# Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

> **NCT00004223** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- Urethral Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00004223
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02-24
- **Primary completion:** 2002-10
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004223, "Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00004223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*